Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Slides:

Advertisements

Similar presentations

COMP8130 and COMP4130 Adrian Marshall Verification and Validation Risk Management Adrian Marshall.

Advertisements

Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.

Save The Date! Fatigue and Arthritis Wednesday 13 th April 2016 Holiday Inn-Southampton Free Health Care Professional Delegate Places Book Early Signed_________________.

EBM --- Journal Reading Presenter ：黃美琴 Date ： 2005/10/27.

A NEW LOOK AT RA Interactive Hot Topics Series

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Introduction to Biosimilars

Primary Care Challenges in Depression - To Treat or Refer?

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Introduction/Background

Diagnosing Rheumatoid Arthritis Early

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Managing Comorbidities in Patients With Rheumatoid Arthritis

Novel Small Molecule Therapies in Rheumatoid Arthritis

Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.

Comparing Treatment Alternatives in Ankylosing Spondylitis

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Pathways in Managing Ulcerative Colitis

When Would You Use Single Inhaler Triple Therapy in COPD?

Decision-making in the eRA of Treating to Target

Disease Activity Assessment Across the RA Continuum

Precision Management of RA and Comorbidities

Introduction. Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases.

Clinical Updates in RA: New Developments and Insights From Washington

Are We Closer to Personalized Medicine in MS?

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

The future of urate-lowering strategies for gout

Case Collection in RA: Highlights of an Interactive Workshop

Should I Stay or Should I Go?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Program Goals Disclaimer Overview Assessing Disease Activity.

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Poor Response to Initial Therapy for Migraine

Biotherapeutics.

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.

Maintenance Therapy in Advanced Ovarian Cancer

What's New in Therapeutic Options for Moderate to Severe RA?

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Current Challenges in Managing Hemophilia

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Communicating With Your Patients About Major Depressive Disorder

Updates in RA, PsA, and Biosimilars

Improving Outcomes in Patients With SSc-ILD

The Patient With Early Stage MF-CTCL

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Disease Burden of VTE Phases of VTE Treatment.

Prioritizing Prevention of HPV-Related Disease

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

Clinical response in patients with early and established RA at month 24. *p

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Rheumatoid Arthritis.

Satisfaction with control of RA

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Treatment Advances for RA

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Biosimilars in Immune-Related Diseases

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis

Learning Goals

Case 1: Introduction (JS)

Validated Quantitative Measures of Disease Activity

Features of Disease Activity Measurement Tools

Features of Disease Activity Measurement Tools (cont)

Assessing Disease Activity in RA

Key Principles

ACR Recommendations for Treating Early RA

Poor Prognostic Features

ACR / EULAR Definitions of Remission

A Tablet-based Application to Facilitate Assessment of RA Disease Activity

The READY Application

Usual Workflow to Collect RA Disease Activity Data

Features of the READY iPad Application

Case 2: Introduction (RM)

Case 2 (cont)

RA Therapies

Switching From DMARDS to Biologics

Switching Among Biologics Due to Lack of Response or Loss of Benefit

Switching Among Biologics Due to Adverse Events

Switching Among Biologics Due to Adverse Events (cont)

Switching Among Biologics Due to Adverse Events (cont)

Abbreviations

Abbreviations (cont)

References